ArticleMediators of inflammation2026
Circulating Platelet-Neutrophil Aggregates as Novel Biomarker for Coagulopathy Diagnosis and Disseminated Intravascular Coagulation Prediction in Sepsis.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating Platelet-Neutrophil Aggregates as Novel Biomarker for Coagulopathy Diagnosis and Disseminated Intravascular Coagulation Prediction in Sepsis.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPlatelet-leukocyte aggregates (PLAs) drive immunothrombosis by promoting leukocyte activation and tissue factor release in sepsis. However, their utility as early predictors of sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC) remains unestablished. This study aimed to develop and validate a PLA-based model for SIC diagnosis and DIC prediction.
methodsA prospective prediction study was conducted with 101 sepsis patients in Beijing Jishuitan Hospital between May 2024 and May 2025. Percentage and mean fluorescence intensity (MFI) of different subtypes of PLAs were measured by flow cytometry. Receiver operating characteristic (ROC) curves and Cox regression were performed, assessing the performance of PLAs to diagnose SIC and predict DIC.
resultsPlatelet-neutrophil aggregate MFI (PNA-MFI) demonstrated excellent diagnostic accuracy for SIC (p < 0.001, AUC = 0.789, 95% CI: 0.699-0.880, cut-off value = 2797, sensitivity = 76.2%, specificity = 78.0%, negative predictive value (NPV) = 83.9%, and positive predictive value (PPV) = 68.8%) and superior DIC prediction (p < 0.001, AUC = 0.781, 95% CI: 0.680-0.883, cut-off value = 2621, sensitivity = 83.3%, specificity = 64.9%, NPV = 92.6%, and PPV = 42.6%). Kaplan-Meier analysis showed that high PNA-MFI patients (PNA-MFI ≥ 2621) were more likely to develop DIC (log-rank p < 0.001, hazard ratio: 6.80 [high PNA-MFI/low PNA-MFI], and 95% CI:2.97-15.61).
conclusionPNA-MFI is a promising biomarker for SIC diagnosis and DIC prediction. While internally validated, external validation is essential prior to clinical implementation, and further multicenter studies are warranted to definitively establish its clinical value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.